


4-Fluorobenzaldehyde-2,3,5,6-d₄

Cat. No.:	HY-W442217	
CAS No.:	931111-27-4	
Molecular Formula:	C ₇ HD ₄ FO	
Molecular Weight:	128.14	
Target:	Isotope-Labeled Compounds	
Pathway:	Others	
Storage:	Pure form	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (780.40 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	7.8040 mL	39.0198 mL	78.0396 mL
		5 mM	1.5608 mL	7.8040 mL	15.6079 mL
10 mM		0.7804 mL	3.9020 mL	7.8040 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (19.51 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (19.51 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (19.51 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	4-Fluorobenzaldehyde-2,3,5,6-d ₄ is the deuterium labeled 4-Fluorobenzaldehyde-2,3,5,6-d ₄ [1].
In Vitro	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA